Case number 2017-1240
Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | ENDO PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC. [OPINION - PRECEDENTIAL] [precedential] (0) |
| May 6, 2019 | 55 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [605101] [17-1240, 17-1455, 17-1887] [PBC] [Entered: 05/06/2019 10:54 AM] (2) |
| Mar 28, 2019 | 54 | JUDGMENT filed. REVERSED. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellee(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [596106] [17-1240, 17-1455, 17-1887] [PBC] [Entered: 03/28/2019 09:43 AM] (2) |
| Mar 28, 2019 | 53 | OPINION filed for the court by Wallach, Circuit Judge; Clevenger, Circuit Judge and Stoll, Circuit Judge. Precedential Opinion. [596105] [17-1240, 17-1455, 17-1887] [PBC] [Entered: 03/28/2019 09:42 AM] (17) |
| Dec 6, 2018 | 52 | Submitted after ORAL ARGUMENT by Mr. Martin Jay Black, Esq. for Endo Pharmaceuticals Inc. and William H. Burgess for Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.--[Edited 12/06/2018 by JAB to correct arguing parties] Panel: Judge: Wallach , Judge: Clevenger , Judge: Stoll. [569856] [JCP] [Entered: 12/06/2018 11:18 AM] (0) |
| Dec 3, 2018 | 51 | AMENDED NOTICE OF ORAL ARGUMENT. Panel: 1812M. Case scheduled Dec 06, 2018 9:30 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 203. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [569425] [JCP] [Entered: 12/03/2018 04:56 PM] (2) |
| Nov 15, 2018 | 50 | Response to oral argument order from the Appellees Teva Pharmaceuticals USA, Inc. and Barr Laboratories, Inc..[565614] [17-1240] [Huiya Wu] [Entered: 11/15/2018 05:51 PM] (3) |
| Nov 15, 2018 | 49 | Response to oral argument order from the Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc..[565484] [17-1240] [William Burgess] [Entered: 11/15/2018 04:06 PM] (3) |
| Nov 15, 2018 | 48 | Response to oral argument order from the Appellant Endo Pharmaceuticals Inc..[565431] [17-1240] [Martin Black] [Entered: 11/15/2018 03:37 PM] (3) |
| Nov 15, 2018 | 47 | ORDER filed withdrawing Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC as parties. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [565353] [JAB] [Entered: 11/15/2018 02:05 PM] (2) |
| Oct 25, 2018 | 46 | Notice from Appellees Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC Notice of Non-Participation. Service: 10/25/2018 by email. [560351] [17-1240] [Brenda Joly] [Entered: 10/25/2018 11:34 AM] (7) |
| Oct 22, 2018 | 45 | NOTICE OF ORAL ARGUMENT. Panel: 1812M. Case scheduled Dec 06, 2018 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 203. Response to Notice of Oral Argument due: 11/15/2018. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [559166] [JAB] [Entered: 10/22/2018 01:52 PM] (2) |
| Oct 11, 2018 | 44 | Notice from Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument (request not to schedule oral argument during the same week as No. 17-2354, 18-1053, 18-1376, or 18-1397). Service: 10/10/2018 by email. [556534] [17-1240] [John O'Quinn] [Entered: 10/11/2018 09:51 PM] (2) |
| Oct 2, 2018 | 43 | Notice from Appellant Endo Pharmaceuticals Inc. regarding conflicts with oral argument (February 4-8, 2019). Service: 10/02/2018 by email. [554258] [17-1240] [Martin Black] [Entered: 10/02/2018 04:06 PM] (3) |
| Aug 8, 2018 | 42 | Notice from Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument ([update from 6/15/2018 letter]: request not to schedule oral argument October 4 or 5, or during the same week as nos. 17-2247, 17-2354, or 17-2348.). Service: 08/08/2018 by email. [541544] [17-1240] [John O'Quinn] [Entered: 08/08/2018 02:17 PM] (3) |
| Jul 2, 2018 | 41 | Notice from Appellant Endo Pharmaceuticals Inc. regarding conflicts with oral argument (September 4-6, 2018). Service: 07/02/2018 by email. [533157] [17-1240] [Martin Black] [Entered: 07/02/2018 02:56 PM] (4) |
| Jun 25, 2018 | 40 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks [SEP, OCT, NOV], or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 07/02/2018. [531702] [MJL] [Entered: 06/25/2018 01:47 PM] (0) |
| Jun 19, 2018 | 39 | 6 paper copies of the Corrected Joint Appendix Brief [37] received from Appellant Endo Pharmaceuticals Inc.. [530481] [CJF] [Entered: 06/19/2018 10:01 AM] (0) |
| Jun 15, 2018 | 38 | Notice from Appellees Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument (request not to schedule oral argument during the same week as no. 17-2490, 17-2247, 17-2354, or 17-2348). Service: 06/15/2018 by email. [529937] [17-1240] [John O'Quinn] [Entered: 06/15/2018 02:54 PM] (2) |
| Jun 12, 2018 | 37 | CORRECTED APPENDIX FILED for Endo Pharmaceuticals Inc. [36]. Number of Pages: 424. Service: 06/12/2018 by email. The paper copies of the appendix should be received by the court on or before 06/21/2018. [529558] [MJL] [Entered: 06/14/2018 04:26 PM] (424) |
| Jun 12, 2018 | 36 | TENDERED from Appellees Actavis LLC, Actavis South Atlantic LLC, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals USA, Inc. and Appellant Endo Pharmaceuticals Inc.. Title: CORRECTED JOINT APPENDIX. Service: 06/12/2018 by email. [528789] [17-1240] [Martin Black] [Entered: 06/12/2018 01:26 PM] (424) |
| Jun 1, 2018 | 35 | NOTICE OF REJECTION: The Joint Appendix [34] is not in compliance with the rules of this court and is therefore rejected for filing. Corrected appendix due 06/15/2018. Service as of this date by the Clerk of Court. [526304] [MJL] [Entered: 06/01/2018 02:17 PM] (2) |
| Jun 1, 2018 | 34 | TENDERED from Appellees Actavis LLC, Actavis South Atlantic LLC, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals USA, Inc. and Appellant Endo Pharmaceuticals Inc.. Title: JOINT APPENDIX. Service: 06/01/2018 by email. [526269] [17-1240]. This appendix has been rejected. See Doc. No. [35]. [Martin Black] [Entered: 06/01/2018 01:42 PM] (0) |
| Jun 1, 2018 | 33 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Actavis LLC, Actavis South Atlantic LLC, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals USA, Inc. and Appellant Endo Pharmaceuticals Inc.. Service: 06/01/2018 by email. [526268] [17-1240] [Martin Black] [Entered: 06/01/2018 01:40 PM] (3) |
| Jun 1, 2018 | 32 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellees Actavis LLC, Actavis South Atlantic LLC, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals USA, Inc. and Appellant Endo Pharmaceuticals Inc.. Service: 06/01/2018 by email. [526263] [17-1240] [Martin Black] [Entered: 06/01/2018 01:33 PM] (3) |
| Jun 1, 2018 | 31 | 6 paper copies of the Reply Brief [30] received from Appellant Endo Pharmaceuticals Inc.. [526211] [CJF] [Entered: 06/01/2018 12:15 PM] (0) |
| May 25, 2018 | 29 | TENDERED from Appellant Endo Pharmaceuticals Inc.. Title: REPLY BRIEF. Service: 05/25/2018 by email. [524690] [17-1240] [Martin Black] [Entered: 05/25/2018 11:29 AM] (37) |
| May 25, 2018 | 30 | REPLY BRIEF FILED for Appellant Endo Pharmaceuticals Inc. [29]. Number of Pages: 26. Service: 05/25/2018 by email. The paper copies of the brief should be received by the court on or before 06/05/2018. [524900] [MJL] [Entered: 05/29/2018 08:27 AM] (37) |
| May 17, 2018 | 28 | Corrected Certificate of Interest for the Appellees Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 05/17/2018 by email. [522649] [17-1240] [Brenda Joly] [Entered: 05/17/2018 04:32 PM] (3) |
| May 17, 2018 | 27 | NOTICE OF DEFICIENCY: The certificate of interest [26] filed by Appellees Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC in 17-1240 is incomplete and therefore cannot be accepted for filing at this time. Item #2 was left blank. You are being afforded the opportunity to correct the deficiency. Please ensure all items are filled out. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [522643] [MJL] [Entered: 05/17/2018 04:16 PM] (0) |
| May 17, 2018 | 26 | Amended Certificate of Interest for the Appellees Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Service: 05/17/2018 by email. [522557] [17-1240] [Brenda Joly] [Entered: 05/17/2018 02:50 PM] (0) |
| May 16, 2018 | 25 | **TEXT ONLY** ORDER granting motion to withdraw Brian Robinson and Brigid Morris [24] filed by Appellees Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals USA, Inc. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [522289] [CFT] [Entered: 05/16/2018 03:31 PM] (0) |
| May 14, 2018 | 24 | MOTION of Appellees Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals USA, Inc. and Barr Laboratories, Inc. to withdraw counsel Brian Robinson and Brigid Morris [Consent: unopposed]. Service: 05/14/2018 by email. [521527] [17-1240] [Huiya Wu] [Entered: 05/14/2018 04:16 PM] (4) |
| May 11, 2018 | 23 | 6 paper copies of the Joinder Brief [19] received from Appellees Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. [520992] [JCP] [Entered: 05/11/2018 10:48 AM] (0) |
| May 10, 2018 | 22 | ORDER granting motion to extend time to file appellant's reply brief and the joint appendix [20] filed by Appellant Endo Pharmaceuticals Inc. The reply brief is due 05/25/2018. The appendix is due 06/01/2018. Service as of this date by the Clerk of Court. [520819] [MJL] [Entered: 05/10/2018 04:33 PM] (2) |
| May 9, 2018 | 21 | 6 paper copies of the Opening Response Brief [18] received from Appellees Actavis LLC, Actavis South Atlantic LLC, Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals USA, Inc. [520417] [JCP] [Entered: 05/09/2018 02:46 PM] (0) |
| May 7, 2018 | 20 | MOTION of Appellant Endo Pharmaceuticals Inc. to extend the time to 05/25/2018 to file the Reply Brief., to extend the time to 06/01/2018 to file the appendix [Consent: unopposed]. Service: 05/07/2018 by email. [519829] [17-1240] [Martin Black] [Entered: 05/07/2018 06:58 PM] (13) |
| May 4, 2018 | 19 | Notice of Joinder for Appellees Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC [17] joining in [18] Response Brief submitted by Appellees Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals USA, Inc., Actavis LLC and Actavis South Atlantic LLC in 17-1240. Service: 05/04/2018 by email. The paper copies of the brief should be received by the court on or before 05/14/2018. Appendix is due 05/11/2018 [519759] [CFT] [Entered: 05/07/2018 04:16 PM] (7) |
| May 4, 2018 | 18 | BRIEF FILED for Appellees Actavis LLC, Actavis South Atlantic LLC, Teva Pharmaceuticals USA, Inc., Barr Laboratories, Inc., and Teva Pharmaceuticals USA, Inc. [16]. Number of Pages: 63. Service: 05/04/2018 by email. The paper copies of the brief should be received by the court on or before 05/14/2018. Appellant's Reply brief and Joint Appendix are due 05/11/2018. [519756] [CFT] [Entered: 05/07/2018 04:09 PM] (77) |
| May 4, 2018 | 17 | TENDERED from Appellees Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York LLC. Title: NOTICE OF JOINDER. Service: 05/04/2018 by email. [519445] [17-1240] [Brenda Joly] [Entered: 05/04/2018 07:32 PM] (7) |
| May 4, 2018 | 16 | TENDERED from Appellees Actavis LLC, Actavis South Atlantic LLC, Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals USA, Inc. and Barr Laboratories, Inc.. Title: RESPONSE BRIEF. Service: 05/04/2018 by email. [519442] [17-1240] [William Burgess] [Entered: 05/04/2018 06:43 PM] (77) |
| Apr 12, 2018 | 15 | CORRECTED ORDER: correcting clerk order [14]; reason: To correct consent status. Service as of this date by the Clerk of Court. [512846] [CFT] [Entered: 04/12/2018 12:14 PM] (2) |
| Apr 12, 2018 | 14 | ORDER granting motion to extend time to file brief [12] filed by Appellees Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals USA, Inc., Actavis LLC and Actavis South Atlantic LLC. Appellees' Actavis LLC, Actavis South Atlantic LLC, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. brief due 05/04/2018. Service as of this date by the Clerk of Court. [512836] [CFT] [Entered: 04/12/2018 11:43 AM] (0) |
| Apr 11, 2018 | 13 | 6 paper copies of the Opening Brief [11] received from Appellant Endo Pharmaceuticals Inc. [512697] [JCP] [Entered: 04/12/2018 07:49 AM] (0) |
| Apr 11, 2018 | 12 | MOTION of Appellees Actavis LLC, Actavis South Atlantic LLC, Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals USA, Inc. to extend the time to 05/04/2018 to file the Appellees' Response Brief.. Any response is due within 10 days of service. [Consent: unopposed]. Service: 04/11/2018 by email. [512694] [17-1240] [William Burgess] [Entered: 04/11/2018 11:58 PM] (6) |
| Apr 6, 2018 | 11 | BRIEF FILED for Appellant Endo Pharmaceuticals Inc. [10]. Number of Pages: 43. Service: 04/06/2018 by email. The paper copies of the brief should be received by the court on or before 04/16/2018. Appellees Actavis LLC, Actavis South Atlantic LLC, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. brief is due 04/20/2018. [511623] [CMP] [Entered: 04/09/2018 10:39 AM] (153) |
| Apr 6, 2018 | 10 | TENDERED from Appellant Endo Pharmaceuticals Inc.. Title: OPENING BRIEF. Service: 04/06/2018 by email. [511335] [17-1240] [Martin Black] [Entered: 04/06/2018 01:37 PM] (153) |
| Mar 16, 2018 | 9 | Note to file: 18-1054 (COMPANION started 03/16/2018) with 17-1240, -1455, -1887. These cases shall be considered companion cases and assigned to the same merits panel for oral argument. [505900] [17-1240, 18-1054] [MJL] [Entered: 03/16/2018 11:29 AM] (0) |
| Mar 15, 2018 | 8 | NOTE TO FILE: FOR PRIOR ENTRIES SEE 17-1094. [505719] [MJL] [Entered: 03/15/2018 04:47 PM] (0) |
| Mar 15, 2018 | 7 | Note to file: The following cases are consolidated: 17-1240 (Lead) with 17-1455 and 17-1887 (Members). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [505708] [17-1240, 17-1455, 17-1887] [MJL] [Entered: 03/15/2018 04:30 PM] (0) |
| Mar 15, 2018 | 6 | ORDER filed. Teva's motion [498338-2] is granted only to the extent that 2017-1444 is withdrawn. Amneal's motion [498221-2] is granted only to the extent that 2017-1094 is withdrawn. Each party shall bear its own costs in 2017-1444 and 2017-1094. The revised official caption for 2017-1240, -1455, -1887 is reflected in the order. The parties are directed to file new briefs in 2017-1240, -1455, -1887, limited to the matters now on appeal. Endo's opening brief is due no later than April 6, 2018. Appellees' response briefs are due no later than April 20, 2018. Endo’s reply brief and the joint appendix are due no later than April 27, 2018. ISSUED AS A MANDATE (as to 2017-1444 and 2017-1094 only): March 15, 2018. Service: 03/15/2018 by clerk. [505691] [17-1240, 17-1444, 17-1094] [LMS] [Entered: 03/15/2018 04:10 PM] (4) |
| Apr 12, 2017 | 5 | Note to file: The following cases are consolidated: 17-1094 (Lead) with 17-1240, -1444, -1455, -1887 (Members). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [423608] [17-1094, 17-1240, 17-1444, 17-1455, 17-1887] [MJL] [Entered: 04/12/2017 04:33 PM] (0) |
| Apr 12, 2017 | 4 | ORDER consolidating appeals (17-1887 with 17-1094, -1240, -1444, -1455). The revised official caption is reflected in the order. Endo Pharmaceuticals Inc.'s opening brief addressing all of these appeals, and Mallinckrodt LLC's response brief addressing only issues associated with 17-1094, -1240, -1444, -1455, are due no later than 05/01/2017. Amneal Pharmaceuticals LLC et al.'s response/reply brief, addressing only issues associated with 17-1094, -1240, -1444, -1455, and Actavis LLC et al.'s response brief, addressing only issues associated with 17-1887, are due no later than 06/12/2017. Endo's reply brief is due no later than 06/26/2017. Service as of this date by Clerk of Court. [423414] [17-1094, 17-1240, 17-1444, 17-1455, 17-1887] [MJL] [Entered: 04/12/2017 11:52 AM] (2) |
| Mar 10, 2017 | 3 | Note to file: The following cases are associated:17-1094 Lead with 17-1240, 17-1444, 17-1455 Consolidated. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [414391] [17-1094, 17-1240, 17-1444, 17-1455] [JCA] [Entered: 03/10/2017 01:13 PM] (0) |
| Nov 18, 2016 | 2 | Note to file: The following cases are consolidated: 17-1094 (Lead) with 17-1240 (Cross-Appeal). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [384634] [17-1094, 17-1240] [MJL] [Entered: 11/18/2016 02:17 PM] (0) |
| Nov 18, 2016 | 1 | Appeal docketed. Received: 11/18/2016. [384631] [MJL] [Entered: 11/18/2016 02:14 PM] (32) |
